RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
-16.16%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$1.06B
AUM Growth
+$1.06B
(-26%)
Cap. Flow
-$58.2M
Cap. Flow
% of AUM
-5.5%
Top 10 Holdings %
Top 10 Hldgs %
61.75%
Holding
64
New
2
Increased
7
Reduced
32
Closed
8
Top Buys
| 1 |
Amicus Therapeutics
FOLD
|
$20.2M |
| 2 |
iRhythm Technologies
IRTC
|
$5.95M |
| 3 |
Solid Biosciences
SLDB
|
$5.19M |
| 4 |
Insulet
PODD
|
$4.61M |
| 5 |
Masimo
MASI
|
$4.34M |
Top Sells
| 1 |
KLRS
Kalaris Therapeutics, Inc. Common Stock
KLRS
|
$14.7M |
| 2 |
Boston Scientific
BSX
|
$12M |
| 3 |
Akero Therapeutics
AKRO
|
$12M |
| 4 |
Stryker
SYK
|
$11M |
| 5 |
Intuitive Surgical
ISRG
|
$8.84M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Scholar Rock
SRRK
$3.14B
| $141M | 13.37% | 4,398,281 -151,600 | -3% | -$4.87M |
|
2
Krystal Biotech
KRYS
$4.27B
| $133M | 12.57% | 737,675 -15,500 | -2% | -$2.79M |
|
|
3
Amicus Therapeutics
FOLD
$2.34B
| $77.8M | 7.35% | 9,533,669 +2,478,779 | +35% | +$20.2M |
|
4
Zymeworks
ZYME
$1.12B
| $57M | 5.39% | 4,788,945 -51,518 | -1% | -$614K |
|
5
Nurix Therapeutics
NRIX
$714M
| $48.1M | 4.55% | 4,051,927 -140,700 | -3% | -$1.67M |
|
6
Replimune Group
REPL
$422M
| $47.8M | 4.51% | 4,898,527 -7,000 | -0.1% | -$68.3K |
|
7
LivaNova
LIVN
$3.08B
| $39.8M | 3.77% | 1,014,139 -29,400 | -3% | -$1.15M |
|
|
8
Akero Therapeutics
AKRO
$3.74B
| $38M | 3.59% | 939,277 -295,932 | -24% | -$12M |
|
9
Immunome
IMNM
$828M
| $36.1M | 3.41% | 5,361,187 +533,161 | +11% | +$3.59M |
|
10
Regenxbio
RGNX
$451M
| $34.3M | 3.24% | 4,794,780 | – | – |
|
11
Beam Therapeutics
BEAM
$1.66B
| $31.4M | 2.97% | 1,610,329 +81,762 | +5% | +$1.6M |
|
12
Stoke Therapeutics
STOK
$1.08B
| $29.8M | 2.82% | 4,485,981 -107,648 | -2% | -$716K |
|
13
Kymera Therapeutics
KYMR
$2.95B
| $26.9M | 2.54% | 983,413 -117,019 | -11% | -$3.2M |
|
14
ADC Therapeutics
ADCT
$345M
| $22.1M | 2.09% | 15,666,731 | – | – |
|
15
Biohaven
BHVN
$1.63B
| $20.9M | 1.97% | 867,454 -37,042 | -4% | -$890K |
|
16
Absci
ABSI
$357M
| $20.7M | 1.96% | 8,253,316 | – | – |
|
|
17
Boston Scientific
BSX
$156B
| $19.5M | 1.84% | 193,283 -119,400 | -38% | -$12M |
|
18
Cogent Biosciences
COGT
$1.69B
| $19.3M | 1.82% | 3,216,026 -338,810 | -10% | -$2.03M |
|
19
Neurogene
NGNE
$264M
| $15.3M | 1.45% | 1,308,063 -11,700 | -0.9% | -$137K |
|
20
89bio
ETNB
$1.34B
| $13.7M | 1.3% | 1,886,444 -280,732 | -13% | -$2.04M |
|
21
Establishment Labs
ESTA
$1.2B
| $13.7M | 1.29% | 335,366 +15,217 | +5% | +$621K |
|
22
Annexon
ANNX
$226M
| $12.2M | 1.15% | 6,300,644 | – | – |
|
23
Celldex Therapeutics
CLDX
$1.47B
| $10.7M | 1.01% | 590,175 -25,600 | -4% | -$465K |
|
24
Fate Therapeutics
FATE
$120M
| $10.2M | 0.96% | 12,872,946 | – | – |
|
25
IDEAYA Biosciences
IDYA
$2.15B
| $8.76M | 0.83% | 534,600 -84,700 | -14% | -$1.39M |
|